open access
The molecular portrait of triple-negative breast cancer: the LAG3 gene single nucleotide polymorphism rs2365094 has no impact on the clinical picture
, 2, 3, 4, 5
Affiliations- Department of Surgical Oncology, Copernicus Provincial Multidisciplinary Centre of Oncology and Traumatology, Lodz, Poland
- Department of General Surgery and Surgical Oncology, Faculty of Medicine and Health Sciences, University of Zielona Gora, Zielona Gora, Poland
- Research Laboratory (CoreLab), Medical University of Lodz, Lodz, Poland
- Copernicus Provincial Multidisciplinary Centre of Oncology and Traumatology, Lodz, Poland
- Department of Oncological Physiotherapy, Medical University of Lodz, Lodz, Poland
open access
Abstract
Introduction. Triple-negative breast cancer (TNBC) is characterized by a lack of oestrogen, progesterone and human epidermal growth factor receptors. It is the one of most heterogeneous and highly-aggressive breast cancers, resulting in fast progression. In humans, the lymphocyte activation gene 3 (LAG3) is located on chromosome 12p13 and encodes an immune-regulatory molecule. The aim of the study was to perform a molecular analysis of LAG3 gene polymorphisms.
Material and method. The presence of single-nucleotide polymorphisms (SNPs) at rs2365094 was determined in 30 TNBC patients and 30 healthy controls using a polymerase chain reaction (PCR) and commercially-available TaqMan SNP Genotyping Assays. SNP status was then compared with the clinical outcome.
Results. The allelic alterations in LAG3 gene SNP in rs2365094 appear to have no influence on the clinicopathological picture among TNBC patients. The carriage rate for a single allele did not differ significantly between patients and controls.
Conclusions. No significant relationship was observed between the rs2365094 SNP status and clinicopathological determinants.
Abstract
Introduction. Triple-negative breast cancer (TNBC) is characterized by a lack of oestrogen, progesterone and human epidermal growth factor receptors. It is the one of most heterogeneous and highly-aggressive breast cancers, resulting in fast progression. In humans, the lymphocyte activation gene 3 (LAG3) is located on chromosome 12p13 and encodes an immune-regulatory molecule. The aim of the study was to perform a molecular analysis of LAG3 gene polymorphisms.
Material and method. The presence of single-nucleotide polymorphisms (SNPs) at rs2365094 was determined in 30 TNBC patients and 30 healthy controls using a polymerase chain reaction (PCR) and commercially-available TaqMan SNP Genotyping Assays. SNP status was then compared with the clinical outcome.
Results. The allelic alterations in LAG3 gene SNP in rs2365094 appear to have no influence on the clinicopathological picture among TNBC patients. The carriage rate for a single allele did not differ significantly between patients and controls.
Conclusions. No significant relationship was observed between the rs2365094 SNP status and clinicopathological determinants.
Keywords
LAG3; triple negative breast cancer; immune checkpoints; immunotherapy
About this articleTitle
The molecular portrait of triple-negative breast cancer: the LAG3 gene single nucleotide polymorphism rs2365094 has no impact on the clinical picture
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Research paper (original)
Pages
111-116
Published online
2023-05-19
Page views
1294
Article views/downloads
325
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2023;73(3):111-116.
Keywords
LAG3
triple negative breast cancer
immune checkpoints
immunotherapy
Authors
Katarzyna Boguszewska-Byczkiewicz
Thomas Wow
Bożena Szymańska
Michał Kośny
Agnieszka Kolacinska-Wow
References (31)- Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017; 161(2): 279–287.
- Burugu S, Gao D, Leung S, et al. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017; 28(12): 2977–2984.
- Nowecki Z, Jagiełło-Gruszfeld A, Pogoda K, et al. Leczenie przedoperacyjne chorych na raka piersi i jego wpływ na postępowanie operacyjne oraz radioterapeutyczne (część 2.). Nowotwory. Journal of Oncology. 2021; 71(2): 79–93.
- Lehmann BD, Jovanović B, Chen Xi, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6): e0157368.
- Yin Li, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1): 61.
- Jurj MA, Buse M, Zimta AA, et al. Critical Analysis of Genome-Wide Association Studies: Triple Negative Breast Cancer . Int J Mol Sci. 2020; 21(16).
- Maruhashi T, Sugiura D, Okazaki IM, et al. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020; 8(2).
- Schmid P, Adams S, Rugo HS, et al. IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22): 2108–2121.
- Jiang H, Ni H, Zhang P, et al. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology. 2021; 10(1): 1943180.
- Andrews LP, Marciscano AE, Drake CG, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017; 276(1): 80–96.
- Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990; 171(5): 1393–1405.
- Shi AP, Tang XY, Xiong YL, et al. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. Front Immunol. 2021; 12: 785091.
- Ma C, Sun X, Shen D, et al. Ectopic expression of LAG-3 in non-small-cell lung cancer cells and its clinical significance. J Clin Lab Anal. 2020; 34(6): e23244.
- Workman CJ, Cauley LS, Kim IJ, et al. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol. 2004; 172(9): 5450–5455.
- Schöffski P, Tan DSW, Martín M, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022; 10(2).
- Du H, Yi Z, Wang L, et al. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. Int Immunopharmacol. 2020; 78: 106113.
- Stovgaard ES, Kümler I, List-Jensen K, et al. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer. Appl Immunohistochem Mol Morphol. 2022; 30(1): 62–71.
- Wu S, Shi X, Wang J, et al. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3. Front Immunol. 2021; 12: 561793.
- Luke J, Patel M, Hamilton E, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. Journal of Clinical Oncology. 2020; 38(15_suppl): 3004–3004.
- Yap T, Wong D, Hu-Lieskovan S, et al. 395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy. Regular and young investigator award abstracts. 2020.
- Wang S, Zhang X, Leng S, et al. Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia. Front Immunol. 2020; 11: 615941.
- Manichaikul A, Lin H, Kang C, et al. Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the Trans-omics for Precision Medicine program. Commun Biol. 2022; 5(1): 362.
- Wang M, Du Qi, Jin J, et al. LAG3 and its emerging role in cancer immunotherapy. Clin Transl Med. 2021; 11(3): e365.
- Al-Eitan L, Qudah MAl, Qawasmeh MAl. Association of Multiple Sclerosis Phenotypes with Single Nucleotide Polymorphisms of , and Genes in a Jordanian Population: A Genotype-Phenotype Study. Biomolecules. 2020; 10(3).
- Guo W, Zhou M, Qiu J, et al. Association of LAG3 genetic variation with an increased risk of PD in Chinese female population. J Neuroinflammation. 2019; 16(1): 270.
- Mewes C, Alexander T, Büttner B, et al. Effect of the Lymphocyte Activation Gene 3 Polymorphism rs951818 on Mortality and Disease Progression in Patients with Sepsis-A Prospective Genetic Association Study. J Clin Med. 2021; 10(22).
- Al-Eitan L, Al Qudah M, Al Qawasmeh M. Candidate gene association analysis of multiple sclerosis in the Jordanian Arab population: A case-control study. Gene. 2020; 758: 144959.
- Lee KM, Baris D, Zhang Y, et al. Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol. 2010; 85(8): 560–563.
- Smigielski EM, Sirotkin K, Ward M, et al. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 2000; 28(1): 352–355.
- Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010; 8: 71.
- Fertal SA, Poterala JE, Ponik SM, et al. Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. Cancers (Basel). 2022; 14(5).